Swedish Orphan Biovitrum (SOBI) has acquired the licensing rights to Belgium-based TiGenix's ChrondroCelet, a cell-based product for the repair of cartilage defects of the knee.
written on 03.04.2014
Sobi signs licencing deal for TiGenix's cell-based therapy
